Antifoam agent

Antifoam Agent (Simethicone / Simeticone): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Common Forms

Simethicone (also spelled simeticone in British and European nomenclature) is the primary medicinal antifoam agent used in dietary and pharmaceutical contexts. Simeticone, also known as simethicone, is an inert silicone-based anti-foaming agent used to alleviate symptoms of excessive intestinal gas, including bloating, abdominal discomfort, and flatulence. Simeticone is a synthetic compound that does not occur naturally in any foods or biological sources.

Chemical Composition: Chemically, simeticone is a mixture comprising 90.5–99% polydimethylsiloxane (PDMS), a silicone-based polymer, and 4–7% silicon dioxide, often in the form of hydrated silica gel, which enhances its stability and efficacy as an antifoam compound. Simethicone is a mixture of fully methylated linear siloxane polymers containing repeating units of polydimethylsiloxane stabilized with trimethylsiloxy end-blocking units, and silicon dioxide. Simethicone contains 90.5–99% of polydimethylsiloxane and 4–7% silicon dioxide. The polydimethylsiloxanes present in simethicone are practically inert polymers having a molecular weight of 14,000–21,000.

Physical State: The normal physical state of simethicone is a water-white to grey, translucent, viscous, oil-like liquid with a density of 0.965–0.970 grams/cubic centimeter having demonstrable immiscibility with water and alcohol.

ATC Classification: In terms of classification, simeticone is categorized as a gastrointestinal agent under the Anatomical Therapeutic Chemical (ATC) classification system with the code A03AX13, specifically denoting silicones used for intestinal therapy.

Common Synonyms and Trade Names: Simethicone is also referred to as dimethylpolysiloxane, polydimethylsiloxane (when used in a pharmaceutical context), or dimethicone with added silicon dioxide. Commercially available chewable tablet dosage forms include Gas Relief™, Gas-X™, Genasyme™, Major-Con™, Mi-Acid™, and Phazyme™.

Dosage Forms: Simethicone can be administered orally as a liquid preparation or as solid form, for example capsules, chewable or swallowable tablets. This medication is available in pharmacies as oral drops, chewable tablets, or softgel capsules. Simethicone has also been used as a pharmaceutical excipient in topical formulations such as ointments and skin protectants.

2. Historical Background and Development

PDMS, the primary component, was first synthesized on a commercial scale in the early 1940s by chemists at General Electric and Dow Corning, initially for industrial applications such as antifoaming agents in manufacturing processes. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.

Historically, the use of antifoam agents dates back to the mid-20th century when food scientists sought solutions to problems of excessive foaming during manufacturing and storage of liquid nutritional products. Foaming can lead to inaccurate dosing, inconvenience in administration, and even gastrointestinal discomfort due to swallowed air.

By the 1970s, following the FDA's review of over-the-counter (OTC) monographs, simethicone transitioned to OTC status in the United States, enabling widespread availability without prescription. Its development reflected a broader shift from industrial to biomedical polymer applications, with over 70 years of subsequent use underscoring its enduring safety profile.

Prior to the advent of synthetic antifoam agents, folk and traditional medicine employed natural plant-derived preparations to address gas and bloating. Their earliest uses can be traced back to folk remedies aimed at alleviating discomfort caused by excessive gas or bloating in the gastrointestinal tract. For centuries, natural oils and plant extracts — such as fennel, ginger, and peppermint — served as the foundation of these remedies. These natural substances exhibited antifoaming properties, breaking down surface tension and allowing trapped gas bubbles to coalesce and be expelled more easily, thus providing relief from indigestion and colic symptoms. With the advent of modern science, the pharmaceutical industry refined these traditional practices, developing purified antifoam agents like simethicone.

The history of simethicone covers more than 50 years. The main properties of simethicone are the defoaming reduction of surface tension and the reduction of surface viscosity and hydrophobicity which enable simethicone to spread easily over surfaces.

3. Key Constituents and Mechanism of Action

3.1 Active Constituents

Chemically, simethicone is a mixture of polydimethylsiloxane and silica gel. Polydimethylsiloxane is a silicon-based compound that is inert and non-toxic; it decreases the surface tension of gas bubbles, leading to their collapse. The silica gel serves to enhance the effectiveness of the polydimethylsiloxane by providing a large surface area for interaction with the gas bubbles.

Silicon dioxide is initially rendered hydrophobic in one of a variety of proprietary processes specific to a particular manufacturer. It should not be used in formulations or processing conditions that are very acidic (below pH 3) or highly alkaline (above pH 10), since these conditions may have some tendency to break the polydimethylsiloxane polymer.

3.2 Mechanism of Action

Simethicone is a silicone compound that functions as a non-systemic surfactant, decreasing the surface tension of gas bubbles in the GI tract. This action results in coalescence and dispersion of the gas bubbles, allowing their removal from the GI tract as flatulence or belching.

Silicone antifoams spread on the surface of aqueous liquids, forming a film of low surface tension and thus causing collapse of foam bubbles. Simethicone reportedly allows mucus-surrounded gas bubbles in the GI tract to coalesce and be expelled.

Simethicone reduces the amount of gas in the intestine. Simethicone has surface activity and is able to reduce the surface tension at the liquid/gas interface. This leads to fusion of gas bubbles and destruction of the foam. Therefore, released gas can be absorbed or removed naturally due to intestinal motility.

An additional proposed mechanism has been described in older literature. As suggested by Debray and co-workers over 40 years ago, simethicone acts as a local barrier that protects the mucosa from irritants, such as hydrochloric acid, acetylsalicylic acid, or bile salts. Simethicone probably interacts with endogenous surface-active substances, protecting the intestinal mucosa.

3.3 Pharmacokinetics

The compound is pharmacologically inert, lacking systemic absorption, metabolism, or excretion through the kidneys, which contributes to its outstanding safety profile across all age groups, including infants and pregnant individuals. Not absorbed following oral administration, it does not interfere with the absorption of nutrients or with gastric secretion, and is excreted unchanged in feces.

When simethicone is ingested, it passes through the stomach and into the intestines without being absorbed into the bloodstream. This makes it a safe option for relieving gas-related symptoms, as it does not interfere with systemic bodily functions. Once in the gastrointestinal tract, it exerts its antifoaming action locally.

4. Scientific Evidence by Area of Use

4.1 Flatulence, Bloating, and Functional Gas Symptoms (General)

Simethicone is a widely used, over-the-counter, non-systemic medication indicated for the relief of gastrointestinal gas-related symptoms such as flatulence, bloating, and postprandial discomfort. It functions as a surface-active agent that facilitates the aggregation and expulsion of gas bubbles from the gastrointestinal tract, thereby alleviating distension and pressure. With its FDA approval dating back to 1952, simethicone has an established role in clinical practice, not only for symptomatic relief but also as an adjunct in diagnostic imaging.

A placebo-controlled study examining simethicone for upper gastrointestinal functional disease was published as early as 1974. Forty-one patients were enrolled in the study, with twenty in the simethicone group and twenty-one in the placebo group. The assigned medication was given 10 minutes before each meal and at bedtime for ten days. Changes in symptoms were evaluated around day five and again around day 10. Symptoms evaluated included gas, heartburn, fullness, full feeling, distension, stuffiness, acid indigestion, bloating, pressure, upset stomach, sour stomach, and pain after eating. Symptoms were evaluated by frequency and severity. When comparing the simethicone group to placebo, researchers observed a significant improvement in all symptoms in the simethicone group at visits on day five and day ten.

Efficacy was not established for the symptomatic relief of immediate postprandial upper abdominal distress (IPPUAD); there is no conclusive evidence that excessive gas causes IPPUAD. Overall, the evidence for symptom relief in unselected populations is considered limited and inconsistent; there is no consistent evidence to support its efficacy in humans for borborygmus, gaseous colic, and flatulence across all clinical settings.

4.2 Functional Dyspepsia

The most methodologically robust human trial specifically examining simethicone in functional dyspepsia was a randomized, double-blind, placebo-controlled study by Holtmann et al. (2002). The aim was to compare the efficacy of simethicone with placebo and the prokinetic cisapride in patients with functional dyspepsia. One hundred and eighty-five patients with functional dyspepsia were randomized and treated in a double-dummy technique with simethicone (105 mg three times daily), cisapride (10 mg three times daily), or placebo (three times daily). Outcome measures were assessed at baseline and after 2, 4, and 8 weeks of treatment (intention-to-treat). At 2, 4, and 8 weeks, treatment with simethicone and cisapride yielded significantly (all P values < 0.0001) better improvement of symptoms compared to placebo. Simethicone was significantly better than cisapride after 2 weeks (P = 0.0007), but the differences were not statistically significant after 4 and 8 weeks. Simethicone and cisapride were significantly better than placebo for symptom control in patients with functional dyspepsia after 2, 4, and 8 weeks of treatment, and simethicone was also superior to the prokinetic cisapride in the first 2 weeks of treatment.

Some modern randomized prospective studies have shown the efficacy of simethicone in patients with traveler's diarrhea and functional dyspepsia. According to clinical studies, the effect of simethicone in the treatment of patients with functional dyspepsia significantly exceeds the effect of placebo, as well as the effect of cisapride, which was used as a comparator drug. The evidence base for functional dyspepsia is considered moderate, resting primarily on a small number of RCTs.

4.3 Gastrointestinal Endoscopy and Diagnostic Procedures

This is the area with the strongest and most consistent clinical evidence for simethicone. Multiple RCTs have demonstrated that the use of antifoaming agents, such as simethicone, significantly improves the quality of small bowel mucosa visualization in small bowel capsule endoscopy (SBCE) by decreasing the presence of bubbles and foam.

A 2011 systematic review and meta-analysis by Wu et al. is one of the pivotal references. The value of supplemental use of simethicone in endoscopy including capsule endoscopy (CE), colonoscopy, and esophagogastroduodenoscopy was examined via a systematic review and meta-analysis of randomized controlled studies. The effects examined included small bowel visualization quality (SBVQ), completion rate, gastric transit time, small bowel transit time, diagnostic yield, efficacy of bowel preparation, degree of air bubbles, and duration time. A total of 13 studies were eligible in this meta-analysis; 4 studies comparing purgative or fasting plus simethicone with purgative or fasting alone for capsule endoscopy were identified. For patients who had supplemental simethicone before CE, the SBVQ was significantly better (OR = 2.84, 95% CI: 1.74–4.65, p = 0.00), and the completion rate was comparable.

Two meta-analyses of randomized controlled trials have reported improved visualization quality with the use of purgative laxatives and an anti-foaming agent, usually in the form of simethicone. As a result, the latest North American and European clinical guidelines support the use of both before capsule endoscopy. Despite this, there is uncertainty as to the optimal dose of simethicone to use.

A 2021 phase III randomized controlled trial examined dose optimization. The trial was conducted comparing high volume (1,125 mg simethicone in 750 ml water) versus standard volume (300 mg simethicone in 200 ml water) solutions, both at 1.5 mg/ml. The primary outcome was adequate bowel preparation, defined as a KODA score >2.25, overall and stratified by the proximal and distal half of the small bowel. A total of 167 patients were randomized (mean age 58.7, 54% female), and the most common indication was obscure gastrointestinal bleeding (71.7%).

Simethicone has been used prior to gastroscopy to enhance visualization and prior to radiography of the intestine to reduce gas shadows. One concern has emerged regarding endoscopic use: use of simethicone in the irrigant fluid has been employed to wash away bubbles; however, there has been recent concern with scope manufacturers advising that simethicone not be used routinely because of simethicone settling in the irrigation channel. This causes a concerning biofilm in the endoscope.

4.4 Irritable Bowel Syndrome (IBS)

Simethicone is usually prescribed to patients with IBS to reduce the feeling of bloating and flatulence, but there were no adequately conducted prospective comparative studies. According to the results of randomized, placebo-controlled studies, treatment with probiotics and simethicone reduces the severity of flatulence and abdominal discomfort in patients with IBS.

The evidence specifically for simethicone in IBS as a monotherapy is weak. When analyzing the published literature data, only two studies were identified, in which 80 patients who received simethicone and 54 patients who received placebo were included. Oswald et al. in 1961 published the results of a placebo-controlled simethicone study at a dose of 50 mg (tablets); the results showed that simethicone was more effective than the comparators. More rigorous modern RCT data on simethicone as a monotherapy in IBS meeting current Rome criteria are sparse.

4.5 Infantile Colic

Researchers also studied simethicone to treat infantile colic, but they did not find it to be effective. This conclusion is supported by multiple lines of evidence. Effects of simethicone in infantile colic have been shown not to differ significantly from treatment with a placebo.

The effect of simethicone on "colicky" (n = 27) infants was tested in a double-blind cross-over study. Three different parameters were used to measure the efficiency of the treatment: interviews, 24-hour records, and behavioral observations. No effects of simethicone on the symptoms of infantile colic could be demonstrated. However, 67% of the infants improved during the treatment, which could be ascribed to a high-grade placebo effect.

The findings from two studies investigating the effects of simethicone were inconclusive or not favourable and were graded as moderate/low quality. Simethicone, which reduces gas production, may actually be helpful for some infants, although several randomized controlled trials noted no difference in reducing colic episodes compared with placebo. Simethicone is not recommended for treatment of infant colic.

4.6 Postoperative Gas Pain

When administered orally, simethicone is used as an adjunct in the symptomatic treatment of flatulence, functional gastric bloating, and postoperative gas pains. Clinical use in the postoperative context is established by convention and clinical guideline rather than large-scale RCT evidence. Simethicone is not useful for ileus, small bowel obstruction, or constipation.

4.7 Exercise-Induced Gastrointestinal Symptoms in Athletes

Simethicone was FDA approved in 1952. Since then, it has been researched for use as a skin protectant, for treatment of Helicobacter pylori, and most recently in endurance athletes to reduce exercise-related GI symptoms. Simethicone has garnered attention among endurance athletes for its potential in mitigating exercise-induced GI symptoms. This remains a nascent area of research with only pilot-level study data available.

4.8 Use in Enteral Nutrition and Infant Formula

Antifoam agents are ingredients commonly used in the formulation of nutritional products, including infant formulas, enteral nutrition, and certain supplements. The most widely used antifoam agents in nutrition are silicone-based compounds, such as simethicone and dimethylpolysiloxane. These compounds work by reducing surface tension, causing gas bubbles to coalesce and dissipate more easily. Simethicone, in particular, has been studied for its safety and efficacy in alleviating symptoms of gas and bloating, especially in infants and adults with gastrointestinal complaints.

5. Body Systems and Health Areas of Association

• Gastrointestinal system (primary): Simethicone is used to treat functional gastric bloating, belching, and to relieve pressure, flatulence, and gas from the digestive system.
• Digestive diagnostic procedures: Clear visualization of the mucosa depends on the absence of air bubbles and foam. Multiple RCTs have demonstrated that the use of antifoaming agents, such as simethicone, significantly improves the quality of small bowel mucosa visualization in SBCE by decreasing the presence of bubbles and foam.
• Skin (topical use): The medically established therapeutic use for simethicone is as an ointment base ingredient, topical drug vehicle, and a skin protectant, as well as an antigas and antiflatulent agent for human application.
• Pediatric GI symptoms: Simethicone is an ideal antifoaming agent that has been used in all age groups to reduce bloating, abdominal discomfort, and abdominal pain.

6. Dosage Forms and Reported Dosages

FDA OTC Monograph (Adults and Children over 12 years, self-medication): The FDA OTC Monograph M002 specifies a maximum daily dose of 500 mg for self-medication with simethicone.

Typical per-dose range: Doses of 25 to 200 mg per dose, every 6 hours, have been suggested for management of gas-related conditions in human beings.

Administration timing: Simethicone is administered orally after meals and at bedtime, usually in up to 4 divided doses daily; infant drops (oral suspension) can be administered in up to 12 doses daily.

Per-dosage-unit range: The preferred dosage ranges for simethicone is in the range of about 20 to 125 mg per dosage unit, generally not to exceed 500 mg/day. The dosage ranges may vary with age and weight of a patient as well as the severity of symptoms.

Pre-endoscopy dosing (off-label): A single dose of 40 mg to 133 mg given orally, 20 minutes to 1 hour prior to various endoscopy, colonoscopy, or GI radiographic procedures is most common.

Capsule endoscopy (clinical trial dosing): A phase III RCT compared high volume (1,125 mg simethicone in 750 ml water) versus standard volume (300 mg simethicone in 200 ml water) solutions, both at 1.5 mg/ml. The optimal dose of simethicone before capsule endoscopy is unknown.

Functional dyspepsia (clinical trial dosing): In the Holtmann et al. 2002 RCT, 185 patients were treated with simethicone 105 mg three times daily.

Children (ages 2–12, per one reference source): Children 2 to 12 years old: 40 mg (0.6 mL) orally after meals and at bedtime, as needed, up to 12 doses per day (maximum 480 mg/day).

7. Safety Profile, Adverse Effects, and Drug Interactions

7.1 General Safety

Simethicone is apparently nontoxic; no adverse effects have been reported. The compound is pharmacologically inert, lacking systemic absorption, metabolism, or excretion through the kidneys, which contributes to its outstanding safety profile across all age groups, including infants and pregnant individuals. The most commonly reported side effects associated with simethicone use include mild nausea, vomiting, and diarrhea.

It is not absorbed and is virtually non-toxic. While its use is well-established in diagnostic procedures, therapeutic studies have sometimes been contradictory.

7.2 Limitations of Use

Other causes of symptoms that could be related to gallstones or heart disease should be kept in mind when utilizing simethicone. Additional signs and symptoms, such as vomiting, hematochezia, and severe abdominal tenderness, require further investigation.

Simethicone's efficacy in relieving gas symptoms is well-documented, but it does not address the underlying causes of excessive gas production. Conditions such as lactose intolerance, irritable bowel syndrome (IBS), and certain dietary choices can lead to increased gas formation. While simethicone can help alleviate the immediate discomfort, identifying and managing the root cause of excessive gas is essential for long-term relief.

7.3 Drug Interactions

Simethicone has no significant drug interactions. However, isolated case reports have documented clinically relevant interactions:

• Levothyroxine: There is a case report of changed absorption of levothyroxine in a child when taking simethicone. Simethicone is not absorbed systemically. A 2025 case report published in PubMed described an 18-day-old boy diagnosed with congenital hypothyroidism (CH) who exhibited elevated TSH levels despite levothyroxine (LT4) treatment. Upon increasing the LT4 dose and observing persistent TSH elevation, further investigation revealed the concurrent use of simethicone-containing colic drops. Literature suggests that simethicone can interfere with LT4 absorption. The colic drops were discontinued, leading to normalized TSH levels. The proposed mechanism is nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Management guidance is to separate the times of administration of thyroid replacement hormones and simethicone by at least 4 hours. Monitoring of serum TSH levels is recommended.
• Carbamazepine: Another case report indicated that carbamazepine toxicity could result when administering carbamazepine with simethicone. In that case, a 45-year-old man with epilepsy on carbamazepine underwent evaluation for symptoms of carbamazepine toxicity. Simethicone was the probable cause of the carbamazepine toxicity. After cessation of simethicone therapy, normal drug levels of carbamazepine were obtained again with the standard dose of the drug. The mechanism of this interaction remains unclear, as there is no known pharmacological interaction of this drug with carbamazepine.

7.4 Endoscope Contamination Concern

Simethicone residue despite endoscope reprocessing has been reported. There has been recent concern with scope manufacturers advising that simethicone not be used routinely because of simethicone settling in the irrigation channel. This causes a concerning biofilm in the endoscope. This is a procedural safety concern rather than a patient safety concern.

7.5 Pregnancy and Lactation

Distribution into milk is not expected; simethicone is not orally absorbed. The FDA has categorized simethicone as Pregnancy Category C.

7.6 Incompatibilities

Simethicone is incompatible with oxidizing agents. It is GRAS (Generally Recognized as Safe) listed and included in the FDA Inactive Ingredients Database for oral emulsions, powders, solutions, suspensions, tablets, and rectal and topical preparations.

8. Formulation in Combination Products

Simethicone is often combined with other gastrointestinal medications, such as antacids, antispasmodics, or digestive enzymes, and various simethicone formulations have been previously disclosed. It is often included in antacid products and is available in both liquid and solid dosage forms.

Fixed-combination products include combinations with magaldrate (for concurrent acid and gas symptoms), with mebeverine and alverine (for functional bowel disorders), with trimebutine (for motility-related conditions), and with N-acetylcysteine as an endoscopic premedication to improve mucosal visibility.

9. Regulatory Status

With its FDA approval dating back to 1952, simethicone has an established role in clinical practice, not only for symptomatic relief but also as an adjunct in diagnostic imaging. The FDA OTC Monograph M002 governs the labeling and use of antiflatulent products for OTC human use, permitting simethicone with a maximum daily dose of 500 mg. Simethicone is GRAS listed and included in the FDA Inactive Ingredients Database.

10. Summary of Evidence Strength by Indication

• Gastrointestinal endoscopy/capsule endoscopy visualization: Strong evidence. Multiple RCTs and a 2011 meta-analysis of 13 studies demonstrate statistically significant improvement in mucosal visualization quality. Supported by North American and European clinical guidelines.
• Functional dyspepsia: Moderate evidence. At least one large, well-designed RCT (n=185) shows superiority over placebo and over cisapride at 2 weeks.
• Symptomatic gas relief (flatulence, bloating, belching) in adults: Moderate evidence for short-term symptom relief; no consistent evidence across all clinical settings.
• Irritable bowel syndrome: Weak evidence as monotherapy. Limited prospective data; there are no adequately conducted prospective comparative studies specifically for IBS.
• Infantile colic: Evidence does not support use. Findings from two studies investigating the effects of simethicone were inconclusive or not favourable and were graded as moderate/low quality. The FDA and StatPearls do not recommend simethicone for infant colic.
• Exercise-induced GI symptoms in athletes: Preliminary/pilot-level evidence only.

References

• Ingold C, Akhondi H. "Simethicone." StatPearls [Internet]. National Library of Medicine (NIH/NCBI), 2023.
• Holtmann G, et al. "A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia." Alimentary Pharmacology & Therapeutics, 2002. PubMed PMID: 12197843.
• Wu L, Cao Y, Liao C, Huang J, Gao F. "Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility." Scandinavian Journal of Gastroenterology, 2011. PubMed PMID: 20977386.
• Lipka S, et al. "A randomized controlled trial of high volume simethicone to improve visualization during capsule endoscopy." PMC, 2021.
• Burta O, Iacobescu C, Mateescu RB, et al. "Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study." Translational Gastroenterology and Hepatology, 2018. PMC6256934.
• "Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines." PMC7202698, 2020.
• "Carbamazepine overdose after exposure to simethicone: a case report." PMC2495000.
• PubMed. "LEVOTHYROXINE-SIMETHICONE DRUG INTERACTION AND PRESENCE OF MACRO-TSH IN AN INFANT WITH CONGENITAL HYPOTHYROIDISM." PubMed PMID: 41798976.
• Drugs.com. "Simethicone Monograph for Professionals." AHFS Drug Information.
• U.S. Food and Drug Administration. "Over-the-Counter (OTC) Monograph M002: Antiflatulent Products for OTC Human Use." FDA, 2021.
• ScienceDirect Topics. "Simethicone – an overview." Elsevier.
• Academia.edu. "Simethicone in the Management of Gastrointestinal Gas: A Comprehensive Clinical Overview." Uva Clinical Anaesthesia and Intensive Care, 2025.
• PubMed. "The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-blind randomized study." PMID: 8566629.
• ClinicalTrials.gov NCT05175131. "Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders." Protocol document.
• PMC12613564. "Efficacy of a mixture of simethicone and tyndallized bacillus coagulans in infant colic: a pilot study on behalf of Italian Society of Pediatrics (SIP)." 2025.